Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories

Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. Several independent studies suggest that higher non-synonymous mutational burden assessed by whole exome sequencing (WES) in tumors is associated with improved objective response...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Ping, Pang, Ling, Arreaza, Gladys, Maguire, Maureen, Chang, Ken C. N., Marton, Matthew J., Levitan, Diane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2016
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881477/
https://www.ncbi.nlm.nih.gov/pubmed/27136543
http://dx.doi.org/10.3390/ijms17050651

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4881477/
https://www.ncbi.nlm.nih.gov/pubmed/27136543
http://dx.doi.org/10.3390/ijms17050651

Ejemplares similares